Abstract Search

ea0073oc3.3 | Oral Communications 3: Pituitary and Neuroendocrinology | ECE2021

Metyrapone treatment in endogenous Cushing’s syndrome. Long term efficacy and safety results of the extension of the phase III/IV study PROMPT

Nieman Lynnette , Boscaro Marco , Carla Scaroni , Deutschbein Timo , Mezosi Emese , Driessens Natacha , Georgescu Carmen Emanuela , Hubalewska-Dydejczyk Alicja , Berker Dilek , Jarzab Barbara , Maiter Dominique , Reincke Martin , Loli Paola , Zampetti Benedetta , Atmaca Raùl M. , Badiu Corin , Beckers Albert , Bolanowski Marek , Cavagnini Francesco , Unger Nicole , Giordano Roberta , Hanzu Felicia , Terzolo Massimo , Bostnavaron Martine , Tőke Judit , Toth Miklos

BackgroundRetrospective studies led to European approval of the steroidogenesis inhibitor Metyrapone for the treatment of endogenous Cushings syndrome (CS). We prospectively showed good efficacy and safety of Metyrapone after 12 weeks (Wk12) treatment in the phase III/IV PROMPT study and now report results of an extension study (EXT) sponsored by HRA Pharma Rare Diseases.DesignThis was a single arm, ope...

2 shares

Endocrine Abstracts

Metyrapone treatment in endogenous Cushing’s syndrome. Long term efficacy and safety results of the extension of the phase III/IV study PROMPT

BiosciAbstracts